ArthroCare Bid Signals Ortho Consolidation

If completed, Smith & Nephew’s acquisition of ArthroCare would help it diversify into the ENT market, but the deal may not get done as analysts speculate that competitors Stryker and J&J could step in with counteroffers. But the interest surrounding Austin, TX-based ArthroCare emphasizes the pressures being put on large joint makers to find new ways of making money in orthopedics.

Pricing pressures on hip and knee implants in the US and Europe continue to drive manufacturers to find ways of diversifying their sales streams or distinguishing themselves from their competitors. Smith & Nephew PLC made the latest move with a $1.7 billion offer to acquire ArthroCare Corp.[See Deal]If completed, the purchase would expand Smith & Nephew’s sports medicine business while helping it diversify into the ear, nose, and throat market. The deal may not get done as analysts speculate that competitors Stryker Corp. and Johnson & Johnson could step in with counteroffers. But the interest surrounding Austin, TX-based ArthroCare emphasizes the pressures being put on large joint makers to find new ways of making money in orthopedics.

Hip and knee makers are struggling against the downward price pressure brought on by the Affordable Care Act in the US and similar pressures in Europe. The response in recent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By 

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.